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Abstract:	
  	
  
MALIGNANCIES	
  ASSOCIATED	
  WITH	
  INFLAMMATORY	
  BOWEL	
  DISEASES.	
  Nicole	
  G.	
  
Jawitz,	
  Deborah	
  D.	
  Proctor.	
  Section	
  of	
  Digestive	
  Diseases,	
  Department	
  of	
  Internal	
  
Medicine,	
  Yale	
  University	
  School	
  of	
  Medicine,	
  New	
  Haven,	
  CT.	
  
	
  
Inflammatory	
  Bowel	
  Diseases	
  (IBD),	
  specifically	
  Crohn’s	
  disease	
  and	
  
ulcerative	
  colitis,	
  have	
  been	
  associated	
  with	
  numerous	
  intestinal	
  and	
  extra-‐
intestinal	
  malignancies. Recent studies have suggested use of immunomodulator
therapies has increased risks of malignancies, including melanoma, non-epithelial skin
cancers, cervical cancer, and bladder and urinary tract cancers. The question regarding
how biologic agents, which became a mainstay therapy of IBD in the early 2000s, have
influenced malignancy risk among patients with IBD has yet to be definitely answered.
The aims of this study were to characterize prevalence of comorbid malignancies
among hospitalized patients with IBD and how it has changed over the past decade, to
develop a sense of the chronology by which malignancies present in IBD patients relative
to the general population, and to identify malignancies that are less well defined in the
context of IBD. The overall hypothesis of this work is that the prevalence of codiagnosed malignancies among hospitalized patients with IBD has changed significantly
over the study period.
This is a cross-sectional analysis characterizing the comorbid malignancies of
hospitalized patients, with and without IBD, across the United States at two time points,
spanning nearly a decade. Using the Healthcare Cost and Utilization Project - Nationwide
Inpatient Sample (HCUP-NIS) database years 2002 and 2003, and 2010 and 2011, the
absolute and percent prevalence of malignancies were calculated for patients with and
without IBD, stratified by age. A prevalence rate ratio was calculated to assess rate of
change of prevalence in patients with IBD relative to patients without IBD.
There was no difference in prevalence of colon cancer among IBD patients in
2010-2011 compared to 2002-2003, across all age groups. Both anorectal and colon
cancer rates were increased among patients with IBD compared to those without. There
was an increase in the co-diagnosis of Non-Hodgkin lymphoma and IBD in the 58-67
year old age group in 2010-2011 compared to 2002-2003. Cervical cancer prevalence
was increased among 38-47 year old women with IBD, and non-epithelial skin cancers
were increased among older IBD patients. There were no statistical differences in rates of
Hodgkin lymphoma, leukemia, melanoma, pancreatic and bladder cancers between
patients with or without IBD.
Substantial changes in the prevalence of several types of cancers among
hospitalized patients with IBD have occurred in the study time period. There continues to
be an increased risk of colon, anal, and rectal cancers. The prevalence of bladder cancer,
pancreatic cancer, melanoma, Hodgkin lymphoma, and leukemias among hospitalized
patients with IBD has not significantly increased among IBD patients in the study period.
Thyroid cancers, non-epithelial skin cancers, non-Hodgkin lymphoma, and cervical
cancer rates were increased among IBD patients relative to the general population.
Further investigation into these associations is warranted.
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Introduction
Inflammatory bowel diseases (IBD), comprised of Crohn’s disease and ulcerative
colitis, are chronic, relapsing and remitting conditions primarily characterized by cycles
of intestinal mucosal inflammation due to defects of barrier function and inappropriate
immunologic activation.1,2
For incompletely understood reasons, likely at least partially related to the
overuse of antibiotics over the past decade, the prevalence of Crohn’s disease and
ulcerative colitis has risen. Between 2000 and 2013, Crohn’s disease rates increased from
214 to 236 per 100,000, while ulcerative colitis rates increased from 235 to 248 per
100,000.3
Although all-cause mortality is significantly increased among patients with IBD
compared to the general population, with a standardized mortality ratio of 1.45 for
Crohn’s disease and 1.21 for ulcerative colitis, over the past 15 years, all-cause mortality,
as well as mortality related to colorectal cancers, digestive neoplasms, and infectious
diseases, has decreased.4 As a result, patients with IBD now expectedly incur longer
durations of disease, making understanding and clearly defining the long-term
complications of IBD has increasingly important. Of particular interest is the
characterization of malignancies that patients with IBD may be at a higher risk of
developing, relative to the general population.
It has been very well documented that patients with long-standing IBD have an
increased risk for developing colorectal cancers, there have been growing concerns that
IBD patients may also be at risk of developing other malignancies. Liver and intrahepatic
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bile duct malignancies, for example, have been loosely associated with IBD, with a
borderline increased risk reported by several European studies.5,6
Associations between IBD and extra-intestinal malignancies have also been
reported in the literature:
Papillary thyroid carcinoma, for instance, was reported at a higher rate in Crohn’s
disease patients, with diagnosis occurring at a significantly younger age when compared
to the general population.6 A 2013 study from the University of Utah reported a 3-5 fold
increase in pancreatic cancer in IBD patients in Utah relative to the general US
population,7 although the overall risk of pancreatic cancer in IBD is not well defined. The
incidence of cervical dysplasia and neoplasia among women with IBD, independent of
infection with human papilloma virus, was reported to be 3 times higher relative to the
general population.8 Renal malignancies have been loosely associated with IBD, with a
recent study suggesting that Crohn’s disease patients, particularly those with a complex
phenotype, had an increased incidence of renal cell carcinoma.9
Furthermore, there have been specific concerns regarding how the risk for
developing malignancies among IBD patients has changed, particularly as the
management of IBD has evolved over the past decade.
Many studies have also reported IBD patients receiving thiopurine therapies are at
increased risk for both melanoma and squamous cell cancers.10 Women with IBD were
reported to be at an even higher risk of developing high-grade cervical lesions or cervical
neoplasia when on immunosuppressive medications.11 Azathioprine use among IBD
patients has been associated with a higher risk of bladder cancer and an increased
incidence of urinary tract cancers.12 In an examination of a large cohort of IBD patients
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within the Swedish Cancer Registry, however, there was no significant overall increase in
the standardized incidence ratio for urinary tract cancers among IBD patients.13
Additionally, there have been concerns regarding the development of rare
lymphoproliferative disorders, as associated with the use of biologic agents. Several
studies have suggested increased incidence of rare leukemias and lymphomas among IBD
patients on these therapies. However, the most recent meta-analysis examining this
question concluded there was no substantial evidence to suggest an increased risk of
malignancy in patients on anti-TNFα therapies.12,13
In addition to defining the malignancy risks inherent to the pathology of IBD, it
has become important to define the modifications to the malignancy risk profile of IBD
patients over the past decade due to our changing therapies and management of IBD.
There are few studies that examine the overall risk of malignancies in patients with IBD
in this manner, and, to our knowledge, there have not been any large cohort studies
characterizing malignancies among IBD patients in the United States.
The question regarding how biologics have influenced malignancy risk among
IBD patients has yet to be definitely answered. To broadly address how these agents may
have affected the malignancies faced by IBD patients, the prevalence of co-morbid
cancer diagnoses among a large cohort of hospitalized IBD patients was determined, at a
two time points: 2002-2003 and 2010-2011. These time points were chosen relative to
the Federal Drug Administration approval of infliximab for use in Crohn’s disease in
1998, followed by approval of adalimumab in 2005, using the assumption that biologic
use was minimal in 2002-2003.
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The results of this cross-sectional analysis characterizing the comorbid
malignancies of hospitalized patients across the United States with IBD at two time
points, spanning nearly a decade are presented in this thesis, assessing the initial
hypothesis that the prevalence of co-diagnosed malignancies among hospitalized patients
with IBD has changed significantly.
Three specific aims of this study were:
1) To characterize prevalence of comorbid malignancies among hospitalized
patients with IBD and how it changed over the study period
2) To develop a sense of the chronology by which malignancies presented in IBD
patients relative to the general population
3) To identify malignancies that were less well defined in the context of IBD, and
that would warrant clinician attention and further investigation

For clarity, this thesis will be presented in several parts, with separate results and
discussions for each category of malignancy, followed by a comprehensive discussion.

5	
  
Materials and Methods
Database:
The Healthcare Cost and Utilization Project - Nationwide Inpatient Sample
(HCUP-NIS) database was examined in the years 2002, 2003, 2010, and 2011. This is an
administrative dataset developed through a Federal-State-Industry partnership sponsored
by the Agency for Healthcare Research and Quality. The HCUP-NIS captures all-payer
inpatient hospitalization data from participating hospitals across the United States. In the
years examined, approximately 1000 hospitals across between 35 to 46 states contributed
data. In each of the years analyzed, de-identified information from ~8 million inpatient
admission stays is provided. Collectively, this data is intended to represent a 20%
stratified sample of all nationwide inpatient admissions for any given year.

Study Design:
The years 2002 and 2003 were chosen as the earlier, reference time point for this
study for several reasons. As infliximab, the first anti-TNFα agent, was approved by the
FDA for use in moderate to severe Crohn’s disease in 1998, with adalimumab approved
in 2005, biologic therapies were relatively novel in 2002-2003. Therefore, for the
purposes of this study, use of these therapies was assumed to be minimal among IBD
patients in 2002-2003. Secondly, although HCUP-NIS data is available from 1998
through 2015, there have been multiple changes to database structure within this
timespan. The most uniformity in data elements and the statistical sampling scheme used
to make national estimates was between the years 2002 and 2011, which was therefore
chosen as the endpoint of this study.
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Using standard International Classification of Diseases, 9th revision (ICD-9)
conventions, patients were identified as having IBD if their hospitalization record carried
any diagnosis code of ulcerative colitis (555.0 – 555.9) or Crohn’s disease (556.0 –
555.9). The IBD patient population examined represents individuals hospitalized both for
disease-related and disease-independent causes. Patients younger than age 18 at the time
of admission were excluded from analysis. Patients who did not carry any diagnosis of
IBD were included in the reference group, the hospitalized “general population”, for each
year of analysis.
Both the hospitalized IBD patient population and general population were further
stratified into 7 cohorts, based on age: 18-27 year olds, 28-37 year olds, 38-47 year olds,
48-57 year olds, 58-67 year olds, 68-77 year olds, and those age 78 and older. For each
cohort, patients were identified as having a co-diagnosed malignancy using single-level,
Clinical Classifications Software diagnosis (DXCCS) codes. DXCCS codes are predefined clusters of ICD-9 codes, a subset of which represent specific groups of
malignancies. The frequency of carrying a diagnosis of malignancy was calculated for
each cohort of patients, both with and without IBD. In the calculation of frequencies for
gender specific malignancies, specifically cervical cancer, patients of the opposite sex
were excluded. A percent prevalence of malignancy was also calculated for each age
cohort in the general population and IBD groups of both 2002-2003 and 2010-2011.

Based on this data, four points of statistical comparison were made between:
1) The 2002-2003 hospitalized IBD population and the 2010-2011 hospitalized
IBD population. This analysis was performed to determine what the relative
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change in risk of a malignancy was among IBD patients at these two time
points.
2) The 2002-2003 hospitalized general population and the 2010-2011 general
population.
3) The 2002-2003 IBD compared to the 2002-2003 general population.
4) The 2010-2011 IBD compared to the 2010-2011 general population

To consolidate these statistical comparisons, prevalence rate ratio was calculated
for each age demographic when possible, using the following equation:

𝑷𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆  𝑹𝒂𝒕𝒆  𝑹𝒂𝒕𝒊𝒐 =
𝑷𝒆𝒓𝒄𝒆𝒏𝒕  𝑷𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆  𝒐𝒇  𝒎𝒂𝒍𝒊𝒈𝒏𝒂𝒏𝒄𝒚  𝒂𝒎𝒐𝒏𝒈  𝑰𝑩𝑫  𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔  𝒊𝒏  𝟐𝟎𝟏𝟎 − 𝟐𝟎𝟏𝟏  
𝑷𝒆𝒓𝒄𝒆𝒏𝒕    𝒑𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆  𝒐𝒇  𝒎𝒂𝒍𝒊𝒈𝒏𝒂𝒏𝒄𝒚  𝒂𝒎𝒐𝒏𝒈  𝑰𝑩𝑫  𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏  𝒊𝒏  𝟐𝟎𝟎𝟐 − 𝟐𝟎𝟎𝟑  
𝑷𝒆𝒓𝒄𝒆𝒏𝒕  𝒑𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆  𝒐𝒇  𝒎𝒂𝒍𝒊𝒈𝒏𝒂𝒏𝒄𝒚  𝒂𝒎𝒐𝒏𝒈  𝒕𝒉𝒆  𝒈𝒆𝒏𝒆𝒓𝒂𝒍  𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏  𝟐𝟎𝟏𝟎 − 𝟐𝟎𝟏𝟏
𝑷𝒆𝒓𝒄𝒆𝒏𝒕  𝒑𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆  𝒐𝒇  𝒎𝒂𝒍𝒊𝒈𝒏𝒂𝒏𝒄𝒚  𝒂𝒎𝒐𝒏𝒈  𝒕𝒉𝒆  𝒈𝒆𝒏𝒆𝒓𝒂𝒍  𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏  𝒊𝒏  𝟐𝟎𝟎𝟐 − 𝟐𝟎𝟎𝟑

This represents the relative change in prevalence of a malignancy among an agematched IBD patient cohort relative to the change in prevalence among patients without
IBD between 2002-2003 and 2010-2011.
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Statistical Methods:
In all analyses, national estimates were derived using appropriate weighting at the
individual patient discharge, hospital, and stratum levels, as indicated by HCUP –NIS
weighting protocol. The standard errors of all reported estimates are less than 30%.
Estimates with standard errors greater than 30% are not reportable by HCUP-NIS
standards. Chi-squared analyses were performed to assess statistical significance, which
was achieved at a pre-determined p-value < 0.05. All statistical analyses were performed
with SPSS Statistics, version 22 (IBM).

Attestation of Work:
Dr. Deborah Proctor and I both contributed to the overall project design, as well
data interpretation, and the final written text of this thesis. I was independently
responsible for data collection, statistical analyses, and the formatting of tables and
figures.
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Colon Cancers:
Results:	
  	
  
In general, the prevalence of colon cancer among hospitalized patients without
IBD across age-matched cohorts has increased slightly from 2002-2003 to 2010-2011,
with prevalence increasing with age (Figure 1a). When comparing the 2002-2003 general
population and 2010-2011 general population cohorts, there were statistically significant
differences detected in the prevalence of colon cancer in the 28-37, 38-47, 48-57, and 5867 year old groups. Increases were from 0.09% to 0.13%, p = 0.001; 0.4% to 0.6%, p=
0.001; 1.0% to 1.1%, p = 0.001; and 1.7% to 1.6%, p = 0.026, respectively (Table 1).
Among hospitalized patients with IBD, the percent prevalence of colon cancer
was similar between age-matched cohorts in 2002-2003 and 2010-2011, with slightly
higher rates reported in all age groups of 2010-2011 (Figure 1b). These differences,
however, were not statistically significant.
When comparing the IBD cohort with age-matched general population in 20022003, there was a significantly higher prevalence of colon cancer reported in IBD patients
aged 28-37 and 38-47 (Figure 1c). These rates were 0.49% in patients with IBD
compared to 0.09% in the general hospitalized population, and 0.8% in IBD versus 0.4%
in the general population, respectively (Table 1). At a crossover point around age 50,
however, the diagnosis of colon cancer became more prevalent in the hospitalized general
population compared to the hospitalized IBD population (Figure 1c). Likewise, the
prevalence of colon cancer in 2010-2011 IBD cohorts was higher than in the age-matched
population in younger cohorts.
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Table 1. Prevalence of Colon Cancer Among Hospitalized Patients in 2002-2003 and 2010-2011

Comparisons of absolute and percent prevalence of colon cancer among hospitalized patients with and without IBD,
stratified by age. A prevalence rate ratio was calculated to assess of rate of change of colon cancer prevalence among
IBD patients relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical
rates of change, while >1 indicates faster change and <1 indicates slower change among IBD patients.
Figure 1. Comparisons of Colon Cancer prevalence among hospitalized patients with and without IBD
a.
b.

c.

d.

Graphical representations of the prevalence of colon cancer among hospitalized patients with IBD (“IBD population”)
and without (“general population”), in 2002-2003 and 2010-2011, stratified by age. Colon cancer prevalence was
compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 2002-2003 and 2010-2011,
the general population and the IBD population in 2002-2003 (c), and the general population and the IBD population in
2010-2011.

The crossover point where rates of colon cancer were higher in the general population as
compared to the IBD population occurred in the older, 68-78 year age group (Figure 1d).
The prevalence rate ratios for all age groups were close to 1, with the exception of the 5867 year olds, where it was 1.26 (Table 1).
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Discussion:
The prevalence of colon cancer among patients with IBD did not decrease with
time as expected. There were no significant changes in the prevalence of colon cancer
among hospitalized patients with IBD in 2010-2011 compared to 2002-2003.
Furthermore, the overall prevalence ratio analysis with ratios close to 1 suggests that the
rate of change in prevalence between 2002-2003 and 2010-2011 in the IBD and general
population cohorts were similar. Therefore, it is most likely that the small, nonstatistically significant increases in the prevalence of colon cancer reflect non-specific
changes in surveillance and overall management of colon cancers.
There are several possible explanations for these findings:
Firstly, there was likely an increased awareness and stringent adherence to colon
cancer screening guidelines during the study period, resulting in more diagnoses of colon
cancer, and therefore an increased prevalence among all hospitalized patients. This is
supported by the finding that the prevalence of colon cancer is higher in the hospitalized
general population in 2010-2011 compared to prior. Furthermore, as patients with IBD
are known to be at increased risk for developing colon cancer, at baseline they have more
frequent surveillance, with higher sensitivity modalities including chromoendoscopy15,
beginning at an earlier age. This would result in higher detection of malignancies relative
to the general population. As expected, this data demonstrated that rates of colon cancer
were higher among patients with IBD, especially earlier age groups. This was consistent
with literature suggesting that patients with IBD of greater than 8 years duration were at
~0.5-1% increased risk of colon cancer annually, compared to the overall population,
whose lifetime risk of colorectal cancers were 4.4-4.7%.16
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Secondly, over the examined time period, there was likely an overall
improvement in the standard of care for patients who developed colon cancer. With better
prognosis and decreased mortality, there would expectedly be a non-specific, cumulative
increase in colon cancer prevalence. One indication this is occurring is the increased
prevalence seen among the older cohorts of the general population in 2010-2011
compared to prior.
Lastly, colon cancer develops over the span of decades. Therefore, although the
data does not demonstrate any substantial decrease in the prevalence of colon cancer, it is
possible the study time period is simply too short to identify effects on mortality.
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Cancer of Rectum and Anus:
Results:
The prevalence of rectal and anal cancers in younger cohorts of hospitalized IBD
patients was not reportable due to limited number of cases. In the 38-47 age group and
older cohorts, the prevalence of rectal and anal cancers was comparable between 20022003 and 2010-2011 IBD cohorts (Figure 2b). The only statistically significant difference
was detected among 68-77 year olds, where prevalence of cancers of the rectum or anus
was reported at 0.5% in 2002-2003 compared to 0.8% in 2010-2011 (p=0.044).
In 2002-2003, the peak prevalence of cancers of the rectum and anus among
hospitalized IBD patients was reported within the 48-57 year old age bracket, whereas in
2010-2011 peak prevalence was reached among 58-67 year olds. The magnitude of the
peak was the same in 2010-2011 as in 2002-2003, at 0.9%. While there was a steady
decrease in prevalence of rectal and anal cancers in 2002-2003 in older age groups, rates
in 2010-2011 remained at 0.8%-0.9% in the 48-57, 58-67, and 68-77 year olds, before
dropping to 0.4% in the 78 and up age group (Table 2).
In comparing the hospitalized general population of 2002-2003 to that of 20102011, statistically increased rates of anorectal cancers were detected across all age
groups, except those aged 78 and older (Figure 2a). This was most apparent in the 48-57
year old cohort, where 0.4% of patients had anorectal cancers in 2002-2003 compared to
0.6% in 2010-2011. The peak prevalence of anorectal cancers within the general
population of both 2002-2003 and 2010-2011 was the same, at 0.6%, reported among
different age cohorts: the 58-67 year olds in 2002-2003 and the 48-57 year olds in 20102011.

14	
  

Table 2. Prevalence of Anorectal Cancers Among Hospitalized Patients in 2002-2003 and 2010-2011

Comparisons of absolute and percent prevalence of anorectal cancers among hospitalized patients with and without
IBD, stratified by age. A prevalence rate ratio was calculated to assess of rate of change of anorectal cancer prevalence
among IBD patients relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects
identical rates of change, while >1 indicates faster change and <1 indicates slower change among IBD patients.
Figure 2. Comparisons of Anorectal Cancer prevalence among hospitalized patients with and without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of anorectal cancers among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of
anorectal cancers was compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 20022003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the general population
and the IBD population in 2010-2011 (d).

In general, the rates of anal and rectal cancers were higher among the IBD
population compared to age-matched cohorts of the general population (Figure 2c). In
2002-2003, rates of anorectal cancer were higher among the IBD population until the 5867 age bracket, where it reached the same prevalence as in the general population, with a
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prevalence rate ratio of 1.5. In 2010-2011, the prevalence among IBD patients was higher
than among the general population in all but the 78 and older cohort (Figure 2d).

Discussion:
As expected, in all age groups the prevalence of anorectal cancers among IBD
patients was higher than among the general population in both 2002-2003 and 20102011. Among hospitalized IBD patients, the prevalence of anorectal cancers did not
change across the study time points, reaching the same peak prevalence.
The overall prevalence trend among hospitalized IBD patients, however, did
change. First, there was an overall slightly higher prevalence of anorectal cancers in older
groups. Although this dataset is not equipped to directly assess how or why prevalence
has changed, the latter finding may suggest that patients with anorectal cancers incurred a
lower mortality rate in 2010-2011 compared to prior. This is further supported by the data
reflecting: 1) a higher prevalence of anorectal cancers in the hospitalized general
population in 2010-2011 compared to prior, and 2) an similar increase in prevalence
among IBD patients compared to age-matched groups of the general population.
The second change in prevalence trend was that peak prevalence of anorectal
cancers shifted to a later cohort among IBD patients while it moved to an earlier point
among the general population. It is likely increased surveillance and diagnosis
contributed to the early shift in the general population. However, this does not explain the
later peak within the IBD cohort. Furthermore, the prevalence ratio analysis demonstrated
a 1.5 time faster rate of change in prevalence of anorectal cancers among IBD patients
aged 58-67 compared to the age-matched general population, supports the idea that an
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IBD specific factor at least partially responsible for the increased prevalence. One
possible explanation is that changing management of IBD has affected the time course
over which patients develop anorectal cancers, with a later onset. A recent study suggests
that IBD patients exhibit higher rates of anal dysplasia compared with the general
population, unrelated to immunosuppressive use,17 which could contribute to the finding
of increased rates of anal cancer. Yet unpublished expert opinion has also indicated 6mercaptopurine use may be associated with increased rates of anal cancer.18 These
findings may both partially explain the increased prevalence of anal cancer among IBD
patients. However, to ultimately define how changes in IBD management have affected
the epidemiology of anorectal cancers would require controlling for both duration of
disease and the medications taken by patients, which is not available in the HCUP-NIS.
The data, overall, suggests anorectal cancers continue to be a class of
malignancies that IBD patients are at a significantly increased risk for developing.
Despite the changes in management of IBD, the cumulative risk of having anorectal
cancer as a patient with IBD appears largely unchanged. However, changing management
of IBD may have affected the time course over which patients with IBD develop
anorectal cancers, which bears further investigation.
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Cancer of Liver and Intrahepatic Bile Ducts:
Results:
Across all age groups of hospitalized IBD patients in 2002-2003, the prevalence
of cancers of the liver and intrahepatic bile ducts was not reportable due to low number of
reported cases. In 2010-2011, the frequency of IBD patients with co-diagnosis of cancer
of liver or intrahepatic bile ducts was large enough to calculate prevalence in several age
groups. Overall, there was a narrow range of prevalence, from 0.2% in those aged 38-47
years old, to a peak of 0.4% in the 58-67 year old cohort (Table 3). In contrast, 58-67
year old patients with IBD in 2002-2003 had a statistically significantly lower prevalence
of intrahepatic bile duct and liver cancers, at 0.2% (p = 0.001).
When comparing hospitalized patients without a diagnosis of IBD in 2002-2003
versus 2010-2011, there were similar rates of liver and intrahepatic bile duct
malignancies among younger patients. However, in the 48-57 age bracket and above,
there were increased rates of these malignancies in 2010-2011 compared to 2002-2003
(Figure 3a).
In 2002-2003, the peak prevalence of these malignancies in the general population
was 0.2%, in the 48-57 year old demographic. This prevalence remained stable in all
older age groups. In 2010-2011, however, the highest prevalence of hepatic and
intrahepatic bile duct malignancies was 0.5%, with this peak reported among the older
cohort of 58-67 year olds. The prevalence of these malignancies decreased steadily in
older age brackets. As a result, the greatest difference in rates of hepatic and intrahepatic
bile duct cancers was recorded in the 58-67 year cohort, with 0.2% of the general
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Table 3.
Prevalence of Liver and Intrahepatic Bile Duct Cancers Among Hospitalized Patients, 2002-2003 & 2010-2011

Comparisons of absolute and percent prevalence of liver and intrahepatic bile duct cancers among hospitalized patients
with and without IBD, stratified by age. A prevalence rate ratio was calculated to assess of rate of change of the
prevalence of these cancers among IBD patients relative to rate of change among patients without IBD. A prevalence
rate ratio value = 1 reflects identical rates of change, while >1 indicates faster change and <1 indicates slower change
among IBD patients. Missing values represent non-reportable data due to limited population size.
Figure 3. Liver and Intrahepatic Bile Duct Cancer prevalence among hospitalized patients with & without IBD

a.

b.

Graphical representations of the prevalence of liver and intrahepatic bile duct cancers among hospitalized patients with
IBD (“IBD population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age.
Prevalences of liver and intrahepatic bile duct cancers were compared between general populations of 2002-2003 and
2010-2011 (a) and the general population and the IBD population in 2010-2011 (b).

population carrying this diagnosis in 2002-2003 compared to 0.5% in 2010-2011
(p=0.001).
As there were very few patients with IBD who also carried a diagnosis of hepatic
and intrahepatic bile duct malignancy, comparisons between patients with IBD and those
without cannot be made. In the only reportable point of comparison in 2002-2003, the 5867 age cohort, the percent prevalence of hepatic and intrahepatic bile duct cancers was
0.2% in both the hospitalized population with and without IBD. In all reportable age
groups in 2010-2011, patients with IBD had rates of liver and intrahepatic bile duct
cancers that were roughly 0.1% lower than in the overall hospitalized population without
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IBD. These were non-statistically significant differences, and the only prevalence rate
ratio that could be calculated, for the 58-67 year olds, was 0.8 (Table 3).

Discussion:
Due to low number of patients in 2002-2003 with co-diagnoses of IBD and liver
and intrahepatic bile duct malignancies, our data is inconclusive with respect to how the
prevalence of these malignancies has changed among IBD patients in the study
timeframe.
Although among 58-67 year old patients with IBD there was a significant increase
in the prevalence of these malignancies in 2010-2011 compared to 2002-2003, at 0.5%
versus 0.2%, respectively, the same change in percent prevalence was seen in the general
population, in same demographic. Additionally, prevalence rate ratio in this age group
was 0.8. This means the change in prevalence of liver and intrahepatic bile duct cancers
among IBD patients from 2002-2003 to 2010-2011 was 20% slower than the rate of
change among the general population, though this not a significant different. Therefore,
the increase in prevalence among the 58-67 year old cohort was likely related to universal
increases in awareness, screening, diagnosis, and outpatient care, rather than IBD specific
pathology or management. Although previously reported studies demonstrated a
borderline significance in the development of cancers of the liver and intrahepatic bile
ducts, this was not supported by our data. Overall, this data suggests that there have been
no significant changes to the risk of IBD patients developing hepatic and intrahepatic bile
duct cancers.
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Hodgkin Lymphoma:
Results:
Across all age groups in 2002-2003, there were very few patients carrying codiagnoses of both IBD and Hodgkin lymphoma, below the threshold of reporting. In
2010-2011 there was an increase in the frequency of IBD patients with Hodgkin
lymphoma: in the 28-37, 38-47, and 48-57 year old age brackets, 0.1% of patients carried
both diagnoses (Table 4).
Table 4. Prevalence of Hodgkin Lymphoma Among Hospitalized Patients in 2002-2003 and 2010-2011

Comparisons of absolute and percent prevalence of Hodgkin lymphoma among hospitalized patients with and without
IBD, stratified by age. A prevalence rate ratio was calculated to assess of rate of change of the prevalence of Hodgkin
lymphoma among IBD patients, relative to rate of change among patients without IBD. A prevalence rate ratio value =
1 reflects identical rates of change, while >1 indicates faster change and <1 indicates slower change among IBD
patients.
Missing
values
represent
non-reportable
data
due
to
limited
population
size.
Figure 4. Comparisons of Hogkin Lymphoma prevalence among hospitalized patients with and without IBD	
  	
  

a.

b.

Graphical representations of the prevalence of Hodgkin lymphoma among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. The prevalence of
Hodgkin lymphoma was compared between general populations of 2002-2003 and 2010-2011 (a) and the general
population and the IBD population in 2010-2011 (b).

In all age cohorts of the 2002-2003 hospitalized general population the prevalence
of Hodgkin lymphoma was 0.1%; the exception was within the 38-47 year old cohort,
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where prevalence reached 0.2%. There was no change in the prevalence of Hodgkin
lymphoma among the hospitalized general population in 2010-2011: point prevalence of
Hodgkin lymphoma continued to be 0.1% in most age groups, with peak prevalence of
0.2% achieved in the 38-47 age demographic (p=0.327). The overall prevalence trend
also mirrored that of 2002-2003. Although the percent prevalence in all cohorts was
comparable, statistically, there were significant differences detected when comparing
rates among the 58-67, 68-77, and age 78 and up cohorts, with p =0.005, 0.001, and
p=0.005, respectively (Table 4).

Discussion:
Based on this limited data, it is impossible to make comparisons between the
prevalence of co-morbid diagnoses of IBD and Hodgkin lymphoma between 2002-2003
and 2010-2011. However, as rates of Hodgkin lymphoma among patients with and
without IBD were similar in 2010-2011, it is unlikely there were substantial changes to
the risk of developing Hodgkin lymphoma as a patient with IBD.
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Non-Hodgkin Lymphoma:
Results:
The prevalence of Non-Hodgkin lymphoma was significantly higher among
hospitalized IBD patients in 2010-2011 compared to 2002-2003 in most age brackets
(Figure 5b). Prevalence rose from 0.2% to 0.5%, p<0.001 in the 38-47 age group, from
0.3% to 0.6%, p=0.044 in the 48-57 age group, 0.7% to 1.1%, p=0.022 in the 58-67 age
group, 0.8% to 1.3%, p=0.029 in the 68-77 age group, and 0.7% to 1.1%, p =0.024 in the
78 and up age group (Table 5). Overall, in 2010-2011, the prevalence of Non-Hodgkin
lymphoma in hospitalized IBD patients approached that of the general hospitalized
population. Peak prevalence in both groups was 1.3% in the 68-77 year old cohort.
In 2002-2003, the highest prevalence of Non-Hodgkin lymphoma in the general
population was reported in the 68-77 year age group, at 1%. Co-diagnosis of NonHodgkin lymphoma among hospitalized patients with IBD was significantly lower in all
age groups, with a peak prevalence of 0.8% in the 68-77 year age group (Table 5, Figure
5c). In 2010-2011, overall, the prevalence of Non-Hodgkin lymphoma diagnosis in the
hospitalized general population increased relative to 2002-2003. The peak prevalence
was 1.3%, in the 68-77 year-old cohort, compared to 1.0% prior (Figure 5d).
Prevalence rate ratios ranged from 1.14 in the 78 and older cohort to 2.5 in the 3847 year olds. Notably, the ratio was 1.75 among the 48-57 year olds (Table 5).
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Table 5. Prevalence of Non-Hodgkin Lymphoma Among Hospitalized Patients in 2002-2003 and 2010-2011

Comparisons of absolute and percent prevalence of Non-Hodgkin lymphoma among hospitalized patients with and
without IBD, stratified by age. A prevalence rate ratio was calculated to assess of rate of change of the prevalence of
Non-Hodgkin lymphoma among IBD patients, relative to rate of change among patients without IBD. A prevalence rate
ratio value = 1 reflects identical rates of change, while >1 indicates faster change and <1 indicates slower change
among IBD patients. Missing values represent non-reportable data due to limited population size.

Figure 5. Comparisons of Non-Hogkin Lymphoma prevalence among hospitalized patients with & without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of Non-Hodgkin lymphoma among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of NonHodgkin lymphoma was compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in
2002-2003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the general
population and the IBD population in 2010-2011 (d).
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Discussion:
There was an increased prevalence of IBD patients with Non-Hodgkin lymphoma
in 2010-2011 relative to 2002-2003, with prevalence among 2010-2011 IBD patients
approaching that of general population. Based on this finding, it is not likely that IBD
patients are at increased risk of developing Non-Hodgkin lymphoma relative to the
general population. However, the substantial increase in prevalence compared to 20022003 is significant. There was a disproportionate rise in lymphoma rates among IBD
patients relative to rise in the general population.
Furthermore, the prevalence ratios of 2.5 and 1.75 in the 38-47 and 48-57 age
demographics, respectively, suggested a 150% and 75% faster increase in prevalence of
Non-Hodgkin lymphoma among IBD patients, relative to rate of increase among the agematched general population. This proportion of the change of prevalence can be thought
of as independently attributable to IBD rather than the universal improvements in
diagnosis, outpatient care, or the overall management of Non-Hodgkin lymphoma, which
also contributes to longevity and hence elevating prevalence.
One potential independent factor leading to increased prevalence of Non-Hodgkin
lymphoma among IBD patients is the utilization of anti-TNFα therapies in treating IBD.
Many studies have suggested a link between these agents and the development of rare,
lymphoproliferative disorders, and while this study does not examine the direct
association between biologic use and lymphomas, it does suggest IBD patients have
incurred higher rates of lymphomas than prior. Further investigation of this association is
warranted.
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Leukemias:
Results:
In the younger age groups (18-27, 28-37, and 38-47), there were few hospitalized
patients with IBD carrying a co-diagnosis of leukemia in 2002-2003; these figures were
below the reporting threshold. In older age groups, the prevalence of leukemia ranged
from 0.3% to 0.6%, with a peak prevalence in the 68-77 year age group. Comparatively,
the prevalence of leukemia in the 58-67 year IBD cohort in 2010-2011 was significantly
higher at 0.9% (p = 0.000). The overall the percent prevalence of IBD patients with
leukemia in 2010-2011 was higher compared to rates in 2002-2003, however these
differences were not statistically significant (Figure 6b, Table 6).
In the 2002-2003 hospitalized general population, the prevalence of leukemia
ranged from 0.2% to 0.8%, trending upwards with age. The prevalence of leukemia in the
2010-2011 general population was similar to the prevalence in 2002-2003, especially
among younger patients (Figure 6a). However, leukemia was more prevalent in older
cohorts (58-67, 68-77, and 78 and up) in 2010-2011 compared to 2002-2003, with rates
approaching 1.0% versus 0.8% prior (p =0.000 in all three groups). Prevalence rate ratios
could not be calculated for the younger age cohorts, due to limited sample size. In
reportable groups, the ratio ranged from 1.2 in the 68-77 year cohort, to 2.25 among the
58-67 year olds (Table 6).
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Table 6. Prevalence of leukemias among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence of leukemias among hospitalized patients with and without IBD, stratified by age. A
prevalence rate ratio was calculated to assess of rate of change of the prevalence of leukemias among IBD patients,
relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical rates of
change, while >1 indicates faster change and <1 indicates slower change among IBD patients.

Figure 6. Comparisons of leukemia prevalence among hospitalized patients with and without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of leukemia among hospitalized patients with IBD (“IBD population”) and
without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of leukemia was
compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 2002-2003 and 2010-2011
(b), the general population and the IBD population in 2002-2003 (c), and the general population and the IBD
population in 2010-2011 (d).
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Discussion:
Overall, rates of leukemia among IBD patients were similar in 2002-2003 and
2010-2011. The exception demonstrated by the data was an increase in the co-diagnosis
of leukemia and IBD in the 58-67 year old age group in 2010-2011, which was
statistically significant. The prevalence rate ratio of 2.25 for this age group indicates a
significantly higher rate of change in the prevalence among IBD patients from 2002-2003
to 2010-2011, compared to the rate of change among the general population. Although
this dataset was not intended to explain changes in prevalence, this prevalence ratio
analysis strongly suggests an IBD-specific factor is responsible for the increased
prevalence. Given the similar prevalence in the general population among younger
groups in both 2002-2003 and 2010-2011, but increased prevalence among older groups,
there was likely an improvement in mortality rates associated with leukemia in the study
time period. This, however, does not fully explain the increased prevalence of leukemia
among the 58-67 year olds. One potential explanation could be that biologic use among
IBD patients has increased lymphoma rates, however this study cannot assess this
association. As in all other age groups there does not appear to be a significant increase in
lymphoma prevalence between 2002-2003 and 2010-2011, it is unlikely this is the case.
Overall, it appears that prevalence of leukemia among IBD patients is comparable
to that of the general population.
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Cancer of Pancreas:
Results:
As expected, patients with IBD in younger age groups very rarely carried a codiagnosis of pancreatic cancer. In 2002-2003, there was a 0.2% prevalence of pancreatic
cancer in hospitalized patients with IBD age 58-67; this rate did not change in older
groups. In comparison, in 2010-2011, a higher peak prevalence of pancreatic cancer was
reported among IBD patients, at 0.4% in the 58-67 year old group (Figure 7b). However,
this difference was not statistically significant (p =0.139). Although a statistically
increased rate of pancreatic cancer was reported in 68-77 year old IBD patients in 20102011 compared to 2002-2003 (p=0.044), the percent prevalence was comparable at 0.2%
in 2002-2003 versus 0.3% in 2010-2011 (Table 7).
Although the percent prevalence of pancreatic cancer in the hospitalized general
population was comparable in the younger age groups of 2002-2003 compared to 20102011, there was a statistically significant difference reported in the 28-37 and 38-47 year
age groups (p= 0.030, p=0.010). There was also a difference in the percent prevalence of
pancreatic cancer in the older age groups: in 2002-2003 the prevalence of pancreatic
cancers in the general population trended to a peak of 0.4% among the 58-67 year old and
68-77 year old cohorts. In 2010-2011, although the peak prevalence occurred in same 5867 year age bracket, the rate of pancreatic cancer was higher, at 0.7% (p=0.000).
In general, the rate of pancreatic cancers among patients with IBD was lower than
among patients without IBD in all age groups of 2002-2003 and 2010-2011 (Figure 7b).
In 2010-2011, the prevalence of pancreatic cancer reached peak magnitude in the 58-67
year age bracket in the both the general population (0.7%) and IBD population (0.4%).
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Table 7. Prevalence of pancreatic cancer among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence of pancreatic cancer among hospitalized patients with and without IBD, stratified by
age. A prevalence rate ratio was calculated to assess of rate of change of the prevalence of pancreatic cancer among
IBD patients, relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical
rates of change, while >1 indicates faster change and <1 indicates slower change among IBD patients. Missing values
represent non-reportable data due to limited population size.
Figure 7. Comparisons of pancreatic cancer prevalence among hospitalized patients with and without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of pancreatic cancer among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of
pancreatic cancer was compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 20022003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the general population
and the IBD population in 2010-2011 (d).

Comparatively, there was a non-significant difference in prevalence of pancreatic cancer
in the 58-67 year cohort of 2002-2003, with 0.2% of IBD patients and 0.4% of all other
patients having pancreatic cancer. In this cohort, the prevalence rate ratio was 1.6. For the
older cohorts, the ratio was near 1 (Table 7).
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Discussion:
Although there were statistically significant changes in rates of pancreatic cancer
among the general population, there were no changes in the prevalence of pancreatic
cancer among hospitalized IBD patients in 2002-2003 and 2010-2011. Furthermore, the
prevalence ratio analysis indicates no change in the rate of change among IBD patients
relative to rate of change in prevalence among in the general population.
Despite literature suggesting that pancreatitis and pancreatic insufficiency occur
more frequently in patients with IBD compared to rest of the population, this data
suggests pancreatic cancer is less likely a concern inherent to the natural pathology of
IBD. It is also unlikely that the risk of developing pancreatic cancer has been
substantially modified as a result of evolving IBD management.

31	
  
Melanoma:
Results:
Overall there were more patients among the hospitalized general population with
melanoma in 2010-2011 compared to in 2002-2003 (Figure 8a). While prevalence of
melanoma was stably low at ~0.1% in the 18-27 and 28-37 year old groups (p=0.462 and
p=0.512, respectively), there was a statistically significant increase in melanoma rates
among patients aged 38-47, with rates of 0.16% compared to 0.2%, p =0.035.
In 2002-2003, a stable peak prevalence of melanoma among hospitalized patients
without IBD was reached, at 0.3%; this occurred in the 58-67 year old cohort. The
prevalence of melanoma decreased to 0.2% in the oldest age cohort. In contrast, in 20102011, there was no clear peak prevalence achieved. Rates of melanoma were highest,
however, among the 68-77 year olds, at 0.6%, significantly higher than the 0.3% of 68-77
year old patients with melanoma in 2002-2003 (p = 0.000) (Table 8).
Very few patients with IBD in the 18-27, 28-37, and 38-47 year old cohorts
carried a co-diagnosis of melanoma. In 2002-2003, the rate of melanoma among the 3847 year old hospitalized patients with IBD were not reportable; in 2010-2011 the rate in
this age cohort was 0.1%. In all other age groups, the prevalence of melanoma among
hospitalized patients with IBD was higher in 2010-2011 than in 2002-2003 (Figure 8b).
In 48-57 year olds the percent prevalence of melanoma was 0.3% in 2002-2003, and was
recorded at the same rate in older groups.
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Table 8. Prevalence of melanoma among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence of melanoma among hospitalized patients with and without IBD, stratified by age. A
prevalence rate ratio was calculated to assess of rate of change of the prevalence of melanoma among IBD patients,
relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical rates of
change, while >1 indicates faster change and <1 indicates slower change among IBD patients. Missing values represent
non-reportable data due to limited population size.
Figure 8. Comparisons of melanoma prevalence among hospitalized patients with and without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of melanoma among hospitalized patients with IBD (“IBD population”)
and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of melanoma was
compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 2002-2003 and 2010-2011
(b), the general population and the IBD population in 2002-2003 (c), and the general population and the IBD
population in 2010-2011 (d).

In 2010-2011, however, there was an upward trend in prevalence of melanoma,
reaching a maximum of 0.7% in patients aged 78 and older (Figure 8d). The prevalence
of melanoma among hospitalized patients with IBD as well as the hospitalized general
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population was comparable in 2002-2003, with rates around 0.2-0.3% (Figure 8c). In
2010-2011, IBD patients had similar rates of melanoma when compared to all other
hospitalized patients. Prevalence rate ratios were near 1 in all age groups except 68-77
year olds, where the ratio was 1.5 (Table 8).

Discussion:
Overall, there were more patients among the hospitalized general population with
melanoma in 2010-2011 compared to in 2002-2003, and major differences in prevalence
trend between these two time points. While a peak prevalence of melanoma was achieved
in 2002-2003, prevalence continued to rise in all age groups, without peaking, in 20102011. The prevalence of melanoma among hospitalized patients with IBD was also
higher in 2010-2011 than in 2002-2003.
An increase in surveillance and diagnosis of melanoma has undoubtedly
contributed to the increasing prevalence among all hospitalized patients. Therapies in the
treatment of melanoma have also changed dramatically over the past decade. With the
introduction of CTLA-4 and PD-1 inhibitors, as well as a host of monoclonal antibody
therapies, the overall prognosis for patients with melanoma is improved.21,22
Although melanoma rates among hospitalized IBD patients have increased, the
prevalence of melanoma was comparable to that of the hospitalized general population in
both 2002-2003 and 2010-2011. This, taken together with prevalence rate ratios near 1,
suggesting a similar rate of change in prevalence among IBD patients compared to the
general population, indicates melanoma prevalence has not changed significantly over the
study time period. Although the dataset does not have enough granularity to directly
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assess the direct association of immunomodulatory therapies on melanoma risk, the data
suggests it is unlikely that either the intrinsic pathology of IBD or changes in the
management of IBD have increased the risks of developing melanoma among IBD
patients.
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Non-epithelial Skin Cancers:
Results:
In hospitalized patients without IBD of all age groups, the overall prevalence of
non-epithelial skin cancers – defined as basal cell, Merkle cell, and squamous cell
carcinomas, as well as carcinoma in situ, was higher in 2010-2011 compared to 20022003 (Figure 9b). In the 2002-2003 general population, prevalence of non-epithelial skin
cancers rose to 0.7% in the group of patients 78 years old and greater. Comparatively, in
the 2010-2011 general population, non-epithelial skin cancer rates approached 1.7%.
In 2002-2003, the frequency of non-epithelial skin cancer diagnoses among the
hospitalized general population and patients with IBD are comparable (Figure 9a). The
highest prevalence of non-epithelial skin cancers in IBD patients was 0.6%, in the 68-77
year demographic; the prevalence among the general population for this same group was
also 0.6%. The only statistically significant difference in the prevalence of non-epithelial
skin cancers between patients with IBD and the general hospitalized population in 20022003 was among 48-57 year olds. In this cohort, 0.4% IBD patients carried a diagnosis of
non-epithelial skin cancer compared to 0.2% of the general population.
In all age groups of 2010-2011, the frequency of non-epithelial skin cancers in
IBD patients was higher compared to the general population (0.6% versus 0.4% in the 4857 year cohort; 1.1% versus 0.5% in the 58-67 cohort; 2% versus 0.6% among the 68-77
year olds) (Figure 9d). The prevalence of non-epithelial skin cancers among patients with
IBD approached 2.4% in the 78-year and older cohort, while the prevalence was 0.5% in
the age-matched 2002-2003 cohort (Table 9, Figure 9c).
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Table 9. Prevalence of non-epithelial skin cancers among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence of non-epithelial skin cancers among hospitalized patients with and without IBD,
stratified by age. A prevalence rate ratio was calculated to assess of rate of change of the prevalence of non-epithelial
skin cancers among IBD patients, relative to rate of change among patients without IBD. A prevalence rate ratio value
= 1 reflects identical rates of change, while >1 indicates faster change and <1 indicates slower change among IBD
patients.
Missing
values
represent
non-reportable
data
due
to
limited
population
size.
Figure 9. Comparisons of non-epithelial skin cancer prevalence among hospitalized patients with &without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of non-epithelial skin cancers among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of nonepithelial skin cancer was compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in
2002-2003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the general
population
and
the
IBD
population
in
2010-2011
(d).

The ratio of prevalence ratios was only significantly increased in the 68-77 and 78
and up cohorts, where ratios were 1.54 and 1.98, respectively (Table 9). Otherwise the
rate of change of prevalence of non-epithelial skin cancers was comparable between the
IBD and general population cohorts between 2002-2003 and 2010-2011.
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Discussion:
The overall prevalence of non-epithelial skin cancers in hospitalized patients of
all age groups is higher in 2010-2011 compared to 2002-2003. In all age-matched
cohorts, the frequency of non-epithelial skin cancers in IBD patients was higher
compared to the 2010-2011 general population. In 2002-2003, the frequency of nonepithelial skin cancer diagnoses among hospitalized general population and patients with
IBD are comparable. Exception of 48-57 year age group, in which 0.4% IBD patients
carried a diagnosis of non-epithelial skin cancer, compared to 0.2% of the general
population.
As with most other cancers, there is likely increased detection in 2010-2011
compared to prior. However for increased diagnosis to be the only cause of the increase
in prevalence, we would expect the rate of increase among IBD patients to be
proportional to increase in the general population. This is not the case. The rate of change
between prevalence in the 2002-2003 versus 2010-2011 general population is less than
rate of change for IBD. Furthermore, the prevalence ratio analyses for the 68-77 and 78
and older cohorts suggests a 54% and 98% increased rate of change in prevalence among
IBD patients relative to the change among the general population. This indicates that
while perhaps there may be non-specific reasons related to universal changes in practice
and expected mortality, the increased rates of non-epithelial skin cancers among IBD
patients may be associated with an additional factor related to the pathology of IBD or
the way we are manage our patients with IBD.
One potential contributing factor is the use of immunomodulator therapies such as
azathioprine and anti-TNFα agents. While our study cannot directly assess these
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associations, it does support the theory that IBD patients are at increased risk for
developing non-epithelial skin cancers, emphasizing the importance of routine skin
exams and increased awareness of these cancers among IBD patients.
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Cervical Cancer:
The prevalence of cervical cancer was significantly increased in 2010-2011
among most age groups of IBD patients, compared to in 2002-2003 (Figure 10b). In both
2002-2003 and 2010-2011 there was a similar trend in prevalence trend across age
groups. In 2002-2003, prevalence peaked in the 48-57 and 68-77 age brackets, at 0.5%.
In 2010-2011, the prevalence peaked among the 38-47 year olds at 1% and the 68-77 year
olds, at 0.8% (Table 10).
Cervical cancer prevalence among the general population was also significantly
increased in most age groups of 2010-2011 compared to prior (Figure 10a). The
distribution of prevalence across age groups was unchanged, with peak prevalence
reported among the 38-47 year olds.
In 2002-2003, cervical cancer rates were significantly lower among IBD
population compared to the general population (in all age groups) (Figure 10c). In 20102011, prevalence of cervical cancer was similar across age-matched groups of patients
with and without IBD (Figure 10d). The prevalence rate ratio was most notable among
the 28-37 year olds, where the rate ratio was 3.75 (Table 10). Among 38-47 year olds, the
prevalence rate ratio was 2.27, and was otherwise near 1 for other reportable groups.
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Table 10. Prevalence of cervical cancer among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence of cervical cancer among hospitalized patients with and without IBD, stratified by
age. A prevalence rate ratio was calculated to assess of rate of change of the prevalence of cervical cancer among IBD
patients, relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical rates
of change, while >1 indicates faster change and <1 indicates slower change among IBD patients. Missing values
represent non-reportable data due to limited population size.

Figure 10. Comparisons of cervical cancer prevalence among hospitalized patients with and without IBD	
  

a.

b.

c.

d.

Graphical representations of the prevalence of cervical cancer among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of
cervical cancer was compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 20022003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the general population
and the IBD population in 2010-2011 (d).
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Discussion:
Rates of cervical cancer increased in general population and IBD population in
2010-2011, most likely related to the increased screening and diagnosis.
The prevalence trend for IBD patients in 2010-2011 was also significantly
different from the general population in that it demonstrated two peak prevalences. The
first peak, among the 38-47 year old IBD patients, is likely partially due to increased
screening and diagnosis. However, the prevalence rate ratio of 2.27 – meaning the rate of
change of cervical cancer prevalence among IBD patients was 127% faster than the rate
of change among the age-matched general population – suggests other factors have
contributed.
The second peak among the 68-77 year old IBD patients, was not seen among the
general population. The explanation for this is unclear. In 2002-2003 there also appears
to be a small peak in this age group, raising the question of whether the IBD alone is a
risk factor for cervical cancer. Additionally, it is possible that changing management of
IBD has played a role in the increased prevalence, although this is less likely, given the
prevalence rate ratio of approximately 1.
Whether or not these changes in prevalence are related to biologic use or infection
with human papilloma virus is unknown, and cannot be assessed with this database.
While further investigation should be undertaken, given other studies correlating cervical
cancer with IBD and these findings, it would be prudent to emphasize the importance of
gynecologic exams for all women with IBD.
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Cancer of Bladder:
Results:
Among hospitalized patients with IBD in 2002-2003, the prevalence of bladder
cancers increased from 0.2% in the 48-57 year demographic to 1.0% in the oldest cohort.
In 2010-2011, it rose steadily to 1.4% in the oldest group. Other than in the group of
patients age 78 and older where the difference in prevalence was statistically significant
(p=0.019), the rates of bladder cancer were comparable between age-matched cohorts in
2002-2003 and 2010-2011 (Figure 11b).
In the general population the prevalence of bladder cancer was comparable in agematched groups of 2002-2003 and 2010-2011 until the 48-57 year age bracket (Figure
11a). In this group, the prevalence in 2002-2003 was 0.2% - the same prevalence of in the
matched cohort of IBD patients – but rose to 0.3% in 2010-2011 (p=0.001). While the
maximum prevalence of bladder cancer among the general population in 2002-2003 was
1.1% the peak prevalence of bladder cancer rose to 1.5% in 2010-2011; this was point of
greatest difference, p<0.001.
The rates of bladder cancer among patients with IBD and the general population
were comparable among all reportable age groups in 2002-2003 (Figure 11c). In most
cases, the percent prevalence was slightly lower in the IBD population, although this was
not statistically significant. In 2010-2011 rates of bladder cancer continued to be slightly
lower in all age-matched groups of the IBD population compared to the general
population (Figure 11d). The prevalence rate ratios of all the older cohorts were near 1.
(Table 11).
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Table 11. Prevalence of bladder cancer among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence of bladder cancer among hospitalized patients with and without IBD, stratified by age.
A prevalence rate ratio was calculated to assess of rate of change of the prevalence of bladder cancer among IBD
patients, relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical rates
of change, while >1 indicates faster change and <1 indicates slower change among IBD patients. Missing values
represent non-reportable data due to limited population size.
Figure 11. Comparisons of bladder cancer prevalence among hospitalized patients with and without IBD	
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b.

c.

d.

Graphical representations of the prevalence of bladder cancer among hospitalized patients with IBD (“IBD
population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of
bladder cancer was compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 20022003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the general population
and the IBD population in 2010-2011 (d).
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Discussion:
Other than the significantly increased prevalence of bladder cancer among IBD
patients aged 78 and older, there were no substantial differences in the rates of bladder
cancer between other age-matched cohorts of 2002-2003 compared to 2010-2011.
Coupled with the findings of increases in bladder cancer prevalence among the general
population and that bladder cancer rates among IBD patients were lower than within the
general population, it is unlikely this class of malignancy is intrinsically concerning to the
innate pathology of IBD.
Although the percent prevalence of bladder cancer was increased in all groups,
prevalence rate ratio near 1, particularly in the 78 and older group, indicates the rate of
change of prevalence among IBD patients from 2002-2003 to 2010-2011 was identical to
that of the general population. This, too, supports the idea that the changes to the
management of IBD in the study time period have not substantially changed bladder
cancer risk. The increased prevalence of bladder cancer demonstrated by this data is
ultimately most likely associated with non-specific factors such as changes in smoking
rates, increased diagnosis, diagnosis at earlier stages, and improved prognosis with better
treatments.
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Cancer of Kidney and Renal Pelvis:
Results:
The prevalence of malignancies of the kidney and renal pelvis was similar in
2002-2003 compared to 2010-2011 among younger IBD patients (Figure 12b). There
were very few patients younger than 37 years old with both IBD and renal malignancies.
In all reportable groups, percent prevalence was ~0.1% lower in 2002-2003 compared to
2010-2011, until the 58-67 age group. These differences were not statistically significant.
Peak prevalence of renal malignancies was 0.6% in the 58-67 year age group in 20022003, a non-significant difference compared to the 0.8% prevalence in 2010-2011
(p=0.188). In 2010-2011 the peak prevalence of renal malignancies increased to 0.9%,
reported in the older 68-77 year age group. Among this cohort in 2002-2003, prevalence
was 0.6% (p=0.010).
There were statistically significant differences in the prevalence of renal
malignancies in all age groups of 2002-2003 versus 2010-2011 of the general population,
although percent prevalence was similar (Figure 12a). Rates of these malignancies were
~0.1% lower in 2002-2003 compared to 2010-2011, until the 48-57 year age group. None
of these differences were statistically significant. In 2002-2003, the prevalence peaked in
the 58-67 age bracket at 0.6%, and was reported at the same rate in older groups. The
peak prevalence within the 2010-2011 general population was higher than in 2002-2003,
at 1.0%, and reported in the older 68-77 year old cohort.
The prevalence of renal malignancies among patients with and without IBD in
2010-2011 was similar, with a non-statistically significant ~0.1% lower prevalence
among IBD patients compared to the general population, in all age groups (Figure 12d).
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Table 12. Prevalence of renal and renal pelvis cancers among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence renal and renal pelvis cancers among hospitalized patients with and without IBD,
stratified by age. A prevalence rate ratio was calculated to assess of rate of change of the prevalence of renal and renal
pelvis cancers among IBD patients, relative to rate of change among patients without IBD. A prevalence rate ratio
value = 1 reflects identical rates of change, while >1 indicates faster change and <1 indicates slower change among
IBD patients. Missing values represent non-reportable data due to limited population size.
Figure 12.
Comparisons of renal and renal pelvis cancer prevalence among hospitalized patients with and without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of renal and renal pelvis cancers among hospitalized patients with IBD
(“IBD population”) and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence
of renal and renal pelvis cancers was compared between general populations of 2002-2003 and 2010-2011 (a), IBD
patients in 2002-2003 and 2010-2011 (b), the general population and the IBD population in 2002-2003 (c), and the
general population and the IBD population in 2010-2011 (d).

Prevalence rate ratio was highest in the 38-47 age group, at 1.33, but was otherwise close
to 1 in all other groups (Table 12).
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Discussion:
Between 2002-2003 and 2010-2011 the prevalence of cancers of the kidney and
renal pelvis has not changed among IBD patients, except in the older age groups (68-77
and 78 and up). During this time period, the prevalence of renal malignancies among the
hospitalized general population increased by the same magnitude when comparing agematched cohorts. Furthermore, the prevalence rate ratio of 0.9 in the 68-77 year old
cohort, where the greatest increase in prevalence among IBD patients was reported,
suggests that the rate of change of prevalence among IBD patients between 2002-2003
and 2010-2011 was actually slightly slower than the rate of change among the general
population. Therefore, although several studies have cited increased rates of renal cell
carcinoma among IBD patients, this data suggests the prevalence is comparable to that of
the general population.
As the trends of prevalence of renal cancers across all age groups were similar
between 2002-2003 and 2010-2011, it is also less likely that the changes in management
of IBD have affected the chronology by which IBD patients develop renal cancers.
However this study is not equipped to directly assess the association between biologic
therapies and development of renal malignancies, and finer analysis will be required to
definitively establish the strength of this association.
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Cancer of Thyroid:
Results:
In comparing the prevalence of thyroid cancers between hospitalized IBD patients
in 2002-2003 and 2010-2011, the only difference detected was in the 38-47 year age
group (Figure 13b). In this age bracket, 0.1% of patients had thyroid cancer in 2002-2003
compared to 0.4% in 2010-2011 (p<0.001). In all other age groups, the prevalence of
thyroid cancer was comparable, with rates generally 0.1% higher in the 2010-2011 versus
2002-2003. These differences were not statistically significant (Table 13).
In the hospitalized general population of 2002-2003, there was also a narrow
range of prevalence of thyroid cancers in each age bracket, between 0.2%-0.3%. In 20102011, the prevalence was approximately 0.1% higher across all age groups, which was
statistically different in all but the 18-27 year old cohort. The overall trend across age
groups of the general population were the same between 2002-2003 and 2010-2011, with
the peak prevalence in the 38-47 year old group, and steady decline in prevalence in older
cohorts (Figure 13a).
In 2002-2003, the same prevalence of thyroid cancer was reported in most age
groups of the IBD and general populations. The 38-47 age group was an exception, with
0.1% of IBD patients carrying a diagnosis of thyroid cancer compared to 0.3% in the
general population (Figure 13c). In this cohort in 2010-2011, the rate of thyroid cancer
was the same as that of the general population, at 0.4% (Figure 13d). The ratio of
prevalence ratios for the 38-47 year age group was 3, whereas it was non-significant in all
other categories, with ratios approximately 1 (Table 13).
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Table 13. Prevalence of thyroid cancer among hospitalized patients in 2002-2003 and 2010-2011

Absolute and percent prevalence thyroid cancer among hospitalized patients with and without IBD, stratified by age. A
prevalence rate ratio was calculated to assess of rate of change of the prevalence of thyroid cancer among IBD patients,
relative to rate of change among patients without IBD. A prevalence rate ratio value = 1 reflects identical rates of
change, while >1 indicates faster change and <1 indicates slower change among IBD patients. Missing values represent
non-reportable data due to limited population size.

Figure 13. Comparisons of thyroid cancer prevalence among hospitalized patients with and without IBD

a.

b.

c.

d.

Graphical representations of the prevalence of thyroid cancer among hospitalized patients with IBD (“IBD population”)
and without (“general population”), in 2002-2003 and 2010-2011, as stratified by age. Prevalence of thyroid cancer was
compared between general populations of 2002-2003 and 2010-2011 (a), IBD patients in 2002-2003 and 2010-2011
(b), the general population and the IBD population in 2002-2003 (c), and the general population and the IBD
population in 2010-2011 (d).
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Discussion:
There was a significant increase in the prevalence of thyroid cancer among the
38-47 year old IBD population in 2010-2011 compared to 2002-2003. Although there
were statistically significant increases in the prevalence of thyroid cancer in most age
groups of the 2010-2011 general population compared to prior, the absolute change in
percent prevalence was only 0.1% in the 38-47 age group, whereas the change in percent
prevalence in the age-matched IBD cohort was 0.3%. Prevalence ratio analysis for this
age group also indicates that thyroid cancer prevalence increased 3 times as quickly
among IBD patients relative to the rate of change among the general population. This
indicates there are unique factors, either intrinsic to the pathology of IBD or the way we
manage IBD, that have driven the increase in prevalence. Of these two possibilities, it is
much more likely that a change in our management of IBD has driven the increase in
prevalence in the timespan examined.
While the manner by which anti-TNFα therapies are related to thyroid
malignancies is unclear, our data certainly suggests there may be an association that bears
further investigation, with attention to histological subtypes of thyroid cancers,
distinctions that were not made within this database. In the interim, it will be important to
screen IBD patients carefully for thyroid malignancies, especially younger patients and
those treated with immunomodulator and biologic therapies.
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Overall Discussion
In summary, this data indicates that there have been substantial changes in the
prevalence of several types of cancers among hospitalized patients with IBD. There
continues to be an increased risk of colon, anal, and rectal cancers. Overall, there have
been no reductions in rates of these malignancies among hospitalized IBD patients in the
past 9 years.
The data also indicate that prevalence of bladder cancer, pancreatic cancer,
melanoma, Hodgkin lymphoma, and leukemias among hospitalized patients with IBD has
not significantly increased. These cancers may not be as significant in the independent
pathology of IBD. In these cancers, the lack of significant changes between the earlier
and later endpoint also indirectly indicates any changes in managing IBD have not
substantially modified the risk of developing these malignancies.
This study has also identified several cancers that may be more strongly
associated with IBD than is currently believed, and thus merit further investigation. These
include thyroid cancer - particularly among younger patients, non-epithelial squamous
cell cancers, non-Hodgkin lymphoma, and cervical cancer. IBD patients demonstrated a
significantly increased rate of these malignancies relative to the rate in 2002-2003, with a
disproportionate rise relative to changes within the general population. Taken together,
this suggests there are independent factors related to the way IBD is managed that is
responsible for their increased prevalence.
As mentioned above, the underlying cause of increased prevalence of specific
cancers among IBD patients cannot be identified in our study. In fact, an increase in
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prevalence among hospitalized patients does not necessarily equate to an increased
prevalence in the population as a whole. It does, however, serve as an indirect indicator
of specific malignancies which are concerning in the IBD population.
There are two major considerations, as discussed above with respect to each
malignancy, in explaining the changing prevalence of cancers among inpatients. The first
involves the universal improvements in the standards for diagnosing and treating each
malignancy, which have undoubtedly improved over the time frame studied. With
increased frequency of diagnosis and improved outpatient management of malignancies,
patients have better overall prognoses. This manifests as a cumulative increase in
prevalence over time.
The second consideration revolves around changes specific to patients with IBD
in the study period. This could include changes in patient demographics, particularly
individual, modifiable risk factors, or the shifts in the paradigm for managing IBD with
biologic therapies.
Although the prevalence rate ratio was used, when possible, to tease apart what
portion of the changes in prevalence for a particular age group was due to either
“universal” or IBD specific factors, the dataset does not provide enough granularity to
definitely associate the cause with our observed effect. Therefore, this study does not and
cannot definitively explain the why cancer prevalence has changed. The data simply
indicates that the management of IBD has modified certain types of malignancies
affecting patients with IBD, which is a step towards fully defining the potential long-term
sequelae of long-standing IBD.
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Limitations:
There are several limitations of our study.
Most significantly, our study only examines the cross section of IBD patients who
are hospitalized. Although all-cause hospitalizations are included in this analysis, the
demographics of patients with IBD studied here are almost certainly different that the
characteristics of the general IBD population, as a whole. Therefore, the prevalence of
cancers in the hospitalized IBD patient population may not represent the prevalence in
the IBD population as a whole. At best, it is an indirect indicator of the types of
malignancies that are concerning in this group.
A second limitation is that this is an administrative database based on billing
records. While it is assumed that only active diagnoses are captured, it is possible that
resolved diagnoses are also recorded, which would falsely elevate the prevalence
analysis.
Lastly, this dataset lacks clinical granularity. Most significantly, the HCUP-NIS
does not capture medication data. Therefore, the salient question regarding how, exactly,
the use of anti-TNFα agents has modified the risks of specific malignancies among IBD
patients is unanswerable. To further examine this question would require a more
comprehensive dataset.
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